Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Soshil Kumar Jain01-04-2018
Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Soshil Kumar JainDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Serum Institute of India Pvt LtdDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sunanda JainDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sunanda JainDisclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sunanda JainBoard Meeting-Outcome of Board Meeting
We would like to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. 12th March, 2018, inter-alia, considered and approved the following to be effective from 12th March, 2018: 1.Elevation of Dr. Rajesh Jain, Joint Managing Director to the position of Managing Director of the Company; and 2.Appointment of Mrs. Sunanda Jain as Whole time Director of the Company for a period of three years....Announcement under Regulation 30 (LODR)-Press Release / Media Release
Panacea Biotec Ltd. is pleased to announce the receipt of Establishment Inspection Report (EIR) from the U.S. Food & Drug Administration ('USFDA') indicating the formal closure of the Inspection conducted by USFDA, at its Pharmaceutical Formulation Facility for Oncology Parenteral and Oral Solids Dosage at Malpur, Baddi, District Solan, Himachal Pradesh, India....Announcement under Regulation 30 (LODR)-Demise
Dear Sir/Madam, We are deeply grieved to inform that Shri Ravinder Jain, Managing Director of the Company has departed for his heavenly abode on February 21, 2018. Accordingly, Shri Ravinder Jain has ceased to be director on the Board of Directors of the Company. Kindly take the above information on your record.I. Unaudited Financial Results (Provisional) For The Quarter And Nine Months Ended 31St December, 2017 Ii. Limited Review Report For The Quarter And Nine Months Ended 31St December, 2017
we would like to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. 13th February, 2018, inter-alia, considered and approved the Unaudited Financial Results (Provisional) of the Company for the quarter and nine months ended 31st December, 2017. A copy of the Statement of Unaudited Financial Results (Provisional) for the quarter and nine months ended 31st December, 2017, approved by the Board of Directors...Board Meeting On 13Th February, 2018 For Approving The Unaudited Financial Results (Provisional) For The Quarter And Nine Months Ended 31St December, 2017
This is to inform you that pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, 13th February, 2018 at New Delhi, inter-alia, to consider and approve the Unaudited Financial Results (Provisional) for the quarter and nine months ended 31st December, 2017....